This company is no longer active
0ZP Stock Overview
Zosano Pharma Corporation, a clinical stage biopharmaceutical company, focuses on providing therapeutics and other bioactive molecules to patients suffering from migraine using its transdermal microneedle system.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Zosano Pharma Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.05 |
| 52 Week High | US$27.28 |
| 52 Week Low | US$0.0005 |
| Beta | 2.73 |
| 1 Month Change | -20.00% |
| 3 Month Change | -79.68% |
| 1 Year Change | -99.76% |
| 3 Year Change | -99.92% |
| 5 Year Change | -99.99% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0ZP | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 0% | -0.5% | 1.3% |
| 1Y | -99.8% | 2.9% | 6.4% |
Return vs Industry: 0ZP underperformed the German Medical Equipment industry which returned -27.6% over the past year.
Return vs Market: 0ZP underperformed the German Market which returned -26.1% over the past year.
Price Volatility
| 0ZP volatility | |
|---|---|
| 0ZP Average Weekly Movement | 918.7% |
| Medical Equipment Industry Average Movement | 4.7% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 0ZP's share price has been volatile over the past 3 months.
Volatility Over Time: 0ZP's weekly volatility has increased from 567% to 919% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 40 | Steven Lo | https://www.zosanopharma.com |
Zosano Pharma Corporation, a clinical stage biopharmaceutical company, focuses on providing therapeutics and other bioactive molecules to patients suffering from migraine using its transdermal microneedle system. Its lead product candidate is Qtrypta (M207), a proprietary formulation of zolmitriptan used for the acute treatment of migraine. The company was founded in 2006 and is headquartered in Fremont, California.
Zosano Pharma Corporation Fundamentals Summary
| 0ZP fundamental statistics | |
|---|---|
| Market cap | €12.75k |
| Earnings (TTM) | -€55.20m |
| Revenue (TTM) | €659.13k |
0.0x
P/S Ratio0.0x
P/E RatioIs 0ZP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0ZP income statement (TTM) | |
|---|---|
| Revenue | US$659.00k |
| Cost of Revenue | US$20.85m |
| Gross Profit | -US$20.19m |
| Other Expenses | US$35.01m |
| Earnings | -US$55.19m |
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -11.26 |
| Gross Margin | -3,063.13% |
| Net Profit Margin | -8,375.11% |
| Debt/Equity Ratio | 0% |
How did 0ZP perform over the long term?
See historical performance and comparison